This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
May 10, 2017
Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma
May 10, 2017
Wilson Therapeutics to host conference call to provide first quarter 2017 business update
May 10, 2017
Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
May 08, 2017
Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017
May 08, 2017
Nexstim Plc Terminates Market Making Agreement with Pareto Securities AB in Nasdaq First North Sweden
May 04, 2017
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases
May 04, 2017
Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
May 03, 2017
GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer
May 02, 2017
Q1 2017 General Market Overview
April 28, 2017
Updated results from Phase 1/2 trial of Betalutin® in NHL accepted for presentation at the International Conference on Malignant Lymphoma in June